Bank of Montreal
CRNX icon

Bank of Montreal’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bank of Montreal’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-147,000
Closed -$2.74M – 3848
2022
Q4 		$2.74M Hold
147,000
– – ﹤0.01% 1641
2022
Q3 		$3.12K Buy
+147,000
New +$3M ﹤0.01% 1597
2021
Q2 		– Sell
-731
Closed -$13K – 3932
2021
Q1 		$13K Sell
731
-3,429
-82% -$53.1K ﹤0.01% 4227
2020
Q4 		$60K Buy
4,160
+2,907
+232% +$40.5K ﹤0.01% 3858
2020
Q3 		$20K Sell
1,253
-903
-42% -$13.8K ﹤0.01% 3835
2020
Q2 		$34K Buy
+2,156
New +$36.8K ﹤0.01% 3605
2020
Q1 		– Sell
-1,402
Closed -$35K – 4199
2019
Q4 		$35K Buy
1,402
+435
+45% +$8.28K ﹤0.01% 4012
2019
Q3 		$15K Buy
967
+41
+4% +$797 ﹤0.01% 4233
2019
Q2 		$23K Buy
926
+873
+1,647% +$21.6K ﹤0.01% 4090
2019
Q1 		$1K Sell
53
-44
-45% -$1.08K ﹤0.01% 4197
2018
Q4 		$3K Buy
97
+49
+102% +$1.38K ﹤0.01% 4236
2018
Q3 		$1K Buy
+48
New +$1.43K ﹤0.01% 4505

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Bank of Montreal's CRNX Position: Q1 2023 in Review

Bank of Montreal sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2023, closing a stake of 147,000 shares — an estimated $2.74M sold.

Bank of Montreal first reported a position in CRNX in Q3 2018 and held it in 12 quarters. The position peaked at $2.74M in Q4 2022. 128 funds tracked by Wall St. Rank hold CRNX as of Q1 2023.

  • Bank of Montreal reported no remaining Crinetics Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Bank of Montreal sold 147,000 Crinetics Pharmaceuticals shares in Q1 2023, an estimated $2.74M.
  • Bank of Montreal first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 12 quarters.
  • Bank of Montreal's Crinetics Pharmaceuticals position peaked at $2.74M in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2023.

Based on Bank of Montreal's 13F filing for Q1 2023, filed 13 Jun 2024.